Venetoclax combined with azacitidine in the treatment of secondary myelodysplastic syndrome following multiple myeloma: a case report and literature review - Summary - MDSpire
Advertisement
Venetoclax combined with azacitidine in the treatment of secondary myelodysplastic syndrome following multiple myeloma: a case report and literature review
To analyze the clinical data of a patient with myelodysplastic syndrome (MDS) secondary to stable multiple myeloma (MM) treated with venetoclax and azacitidine, and to review relevant literature.
Approach:
Patient Case: A 74-year-old male with a history of multiple myeloma developed secondary MDS characterized by refractory anemia with excess blasts-2 (MDS-RAEB-II) 51 months post-MM diagnosis and was treated with venetoclax and azacitidine.
Literature Review: The article includes a review of literature regarding the efficacy of venetoclax and azacitidine in treating secondary MDS following multiple myeloma.
Key Findings:
The patient achieved morphological partial remission of MDS after the first treatment course with venetoclax and azacitidine.
Non-adherence to continuous treatment contributed to the patient's eventual death from a secondary infection.
Interpretation:
Adherence to treatment is crucial for successful outcomes.
Limitations:
The study is based on a single patient case, limiting the generalizability of the findings.
Retrospective analysis may introduce biases in data interpretation.
Conclusion:
This case emphasizes the importance of treatment adherence.
A targeted radiopharmaceutical improves CAR T activity in neuroblastoma models, engineered Tregs suppress allergic asthma, and new gene therapy platforms target MMA and the brain
